EcoDrugPlus

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSTNIG00000011022
Gene Symbol: CACNA2D1A
2 Cross references
226 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSTNIG00000014763
Gene Symbol: CACNA2D2A
2 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSTNIG00000003014
Gene Symbol: CACNB1
2 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 2a

Ensembl ID : ENSTNIG00000017111
Gene Symbol: CACNB2A
2 Cross references
201 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1a

Ensembl ID : ENSTNIG00000019728
Gene Symbol: CACNG1A
2 Cross references
194 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSTNIG00000011944
Gene Symbol: CACNG4B
2 Cross references
189 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5a

Ensembl ID : ENSTNIG00000014130
Gene Symbol: CACNG5A
2 Cross references
184 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6a

Ensembl ID : ENSTNIG00000018190
Gene Symbol: CACNG6A
2 Cross references
182 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSTNIG00000018192
Gene Symbol: CACNG7A
3 Cross references
184 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8a

Ensembl ID : ENSTNIG00000018191
Gene Symbol: CACNG8A
2 Cross references
166 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSTNIG00000010032
Gene Symbol: CASR
2 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSTNIG00000019197
Gene Symbol: CACNA2D1
3 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).